ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 179 filers reported holding ARCUS BIOSCIENCES INC in Q2 2022. The put-call ratio across all filers is 2.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $11,336 | -12.3% | 744,298 | +8.7% | 0.03% | -14.7% |
| Q1 2024 | $12,933 | +25.5% | 685,025 | +26.9% | 0.03% | +17.2% |
| Q4 2023 | $10,309 | +11.1% | 539,727 | +4.4% | 0.03% | +3.6% |
| Q3 2023 | $9,278 | -25.3% | 516,864 | -15.4% | 0.03% | -26.3% |
| Q2 2023 | $12,413 | -12.2% | 611,172 | -21.1% | 0.04% | -22.4% |
| Q1 2023 | $14,132 | -10.7% | 774,792 | +1.2% | 0.05% | -14.0% |
| Q4 2022 | $15,832 | -99.9% | 765,550 | +23.0% | 0.06% | -10.9% |
| Q3 2022 | $16,286,000 | +15.1% | 622,564 | +11.5% | 0.06% | +18.5% |
| Q2 2022 | $14,155,000 | -43.7% | 558,602 | -29.9% | 0.05% | -37.9% |
| Q1 2022 | $25,156,000 | -27.8% | 797,091 | -7.5% | 0.09% | -25.0% |
| Q4 2021 | $34,857,000 | +27.3% | 861,294 | +9.7% | 0.12% | +13.7% |
| Q3 2021 | $27,377,000 | +219.8% | 785,106 | +151.8% | 0.10% | +229.0% |
| Q2 2021 | $8,562,000 | – | 311,796 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $29,404,284 | 19.15% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,864,970 | 6.40% |
| Octagon Capital Advisors LP | 2,172,000 | $39,617,280 | 5.70% |
| Boxer Capital, LLC | 1,432,200 | $26,123 | 1.28% |
| PFM Health Sciences, LP | 1,559,947 | $28,453,433 | 1.26% |
| SECTORAL ASSET MANAGEMENT INC | 293,646 | $5,356,103 | 1.03% |
| DAFNA Capital Management LLC | 175,217 | $3,195,958 | 0.96% |
| Ikarian Capital, LLC | 230,000 | $4,195,200 | 0.95% |
| Tejara Capital Ltd | 50,000 | $912,000 | 0.47% |
| Capital Impact Advisors, LLC | 20,501 | $373,938 | 0.46% |